Hepatitis A vaccine gives long-lasting protection
NEW YORK (Reuters Health) - Hepatitis A infections, usually transmitted via contaminated food, can cause debilitating illness, but protection afforded by the hepatitis A vaccine last more than a decade, a new study shows.
In fact, antibodies against hepatitis A virus persist for up to 27 years after vaccination, report investigators from the Centers for Disease Control and Prevention in Atlanta and the Alaska Native Tribal Health Consortium in Anchorage.
Lead author Dr. Laura L. Hammitt, now at the Kenya Medical Research Institute/Welcome Trust Collaboration in Kilifi, and colleagues enrolled 144 children and 128 adults who responded to a three-shot series of hepatitis A vaccine to assess the persistence of antibodies.
The adults had received a primary dose of hepatitis A vaccine, with a second vaccination given 1 month later and a third given 12 months after the first.
The children were between 3 and 6 years of age and were given three doses at various intervals over the course of a year.
Hammitt’s team collected blood samples 1 month after vaccination and again 1 to 10 years after vaccination to test for anti-hepatitis A antibodies. The researchers calculated long-term antibody persistence based on the observed rate of decline in concentrations.
“The estimated duration of antibody persistence was 21-27 years, depending on the vaccination schedule,” Hammitt and colleagues write in the Journal of Infectious Diseases.
They say the findings show that protective levels of anti-hepatitis A antibodies are retained for at least 10 years after vaccination. “Hepatitis A booster doses after completion of the primary vaccination series do not appear to be warranted and are not currently recommended,” the CDC team advises.
Nonetheless, they point out, antibody concentrations do decline over time and ongoing monitoring is needed “to assess whether persons vaccinated as children will be protected throughout adulthood.”
SOURCE: Journal of Infectious Diseases, December 15, 2008.
--------------------------------------------------------------------------------------------Related Posts:
By Will Boggs, MD NEW YORK (Reuters Health) - Protection against hepatitis B appears to drop off in adolescents who got the hepatitis B vaccine beginning at birth, according to a new report. Dr. Stephanie R. Bialek from the US Centers for Disease Control and Prevention, Atlanta, Georgia, and colleagues evaluated the occurrence of breakthrough infections and
Full Post: Hepatitis B vaccine protection may wane in teens
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - An experimental malaria vaccine is the most promising yet, protecting up to 65 percent of infants from infection in two studies in Africa, researchers reported on Monday. Separate tests in Kenya and Tanzania showed GlaxoSmithKline’s vaccine called RTS,S could protect babies and toddlers from infection with malaria
Full Post: Glaxo malaria vaccine protects babies, children
--------------------------------------------------------------------------------------------
BEIJING (Reuters) - A group of 101 mothers have written to China’s Communist Party leadership for help after their toddlers were denied kindergarten places for testing positive for hepatitis B. China has passed laws in recent years reversing a ban on its 120-130 million hepatitis B carriers from the civil service, and banning companies from using
Full Post: Hepatitis bars China toddlers from kindergarten
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - A vaccine to protect against infection with the bird flu virus, the pathogen experts fear is capable of causing pandemic disease in humans, proved safe and effective in a preliminary clinical trial with children, mirroring the results of a recent trial conducted in adults, Hungarian researchers report in the Pediatric
Full Post: Bird flu vaccine protects children
--------------------------------------------------------------------------------------------
By Megan Rauscher NEW YORK (Reuters Health) - Even in an influenza season where there is not an optimal match between circulating strains of influenza and the strains contained in the influenza vaccine, the vaccine is likely to significantly protect young children, ages 6 to 59 months, against influenza, new research indicates. Influenza vaccine effectiveness has not
Full Post: Influenza vaccine effective in young children